Articles tagged with Pancreatic Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
Researchers have identified a group of deregulated genes in pancreatic cancer that may serve as potential therapeutic targets. These long non-coding RNAs, when silenced, reduced tumor aggressiveness and characteristics such as proliferation and invasion.
A trial involving 1000 patients with Lynch syndrome found that a daily dose of resistant starch reduced cancers in other parts of the body by over half, particularly upper GI cancers. The effect persisted for 10 years after stopping the supplement.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Researchers at Cold Spring Harbor Laboratory have developed a rapid organoid screening test that can predict response to neoadjuvant chemotherapy in pancreatic cancer patients. This test may help optimize personalized treatment plans and improve patient outcomes.
Researchers used radiomics-based machine learning models to detect pancreatic cancer on prediagnostic CT scans, identifying it up to 386 days before clinical diagnosis. The AI model showed high accuracy and specificity, with a range of 94-98%, and was unaffected by image variations.
Combination chemotherapy with FOLFIRINOX before surgery increased survival in patients with borderline resectable pancreatic cancer, outperforming FOLFIRINOX plus radiotherapy. The study demonstrated the effectiveness of neoadjuvant chemotherapy in improving outcomes for these patients.
A new study found that most patients with pancreatic cancer diagnosed through regular screenings had early-stage disease, leading to long-term survival. The study suggests that surveillance programs can help detect precancerous conditions and cancers early, when they are most treatable.
A preclinical study by Cedars-Sinai Cancer and Johns Hopkins University has discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice. The treatment, which combines anti-PD-1 immunotherapy antibody, FAKi, and CXCR4, prevents cancer metastasis and bolsters the immune system.
Researchers have discovered a key protein regulating pancreatic cancer cell growth and spread, which can be manipulated to reverse the process. Boosting levels of GREM1 has been shown to turn back aggressive tumours, making them easier to treat.
Researchers found that suppressing an enzyme called MSRA, which fixes oxidative damage to proteins, sparks the metastatic spread of pancreatic cancer cells. The discovery suggests that similar switches may exist in other cancers and lays the groundwork for redox-based targeted therapies.
A study published in Molecular Cell has identified a protein, MSRA, whose level of expression acts as a molecular switch between primary cancer growth and metastasis in PDA cells. The researchers found that high levels of MSRA expression keep the growing cells as part of the primary tumor, while low levels trigger metastasis.
A recent scientific review suggests that the oral microbiome may hold key answers to pancreatic cancer development, diagnosis, and treatment. The study found a distinct association between oral microbiome patterns and pancreatic tumors, with certain disease-driving bacteria identified in both.
Researchers from Japan and the US share new technologies and blood biomarkers to detect pancreatic cancer and identify high-risk individuals. The findings aim to decrease cancer mortality rates by developing attractive new methods for early diagnosis.
A drug targeting IDH1 mutations in select cancers also inhibits wild-type form under certain conditions, making it a promising therapeutic option. Laboratory experiments and mouse models demonstrate the efficacy of Ivosidenib against various cancer types, including pancreatic, colorectal, ovarian, and lung cancer.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
Researchers at Yale University have discovered a potentially effective treatment for advanced pancreatic neuroendocrine tumors, with a combination of capecitabine and temozolomide yielding longer progression-free survival rates and higher response rates than temozolomide alone.
Researchers found that combining chemotherapy with immunotherapy increased one-year survival rates for patients with advanced pancreatic cancer, with anti-PD-1/chemo regimen showing the highest response. The study identified key immune system biomarkers associated with better outcomes, offering new hope for precision oncology.
The new guidelines expand indication for screening to all with BRCA 1/2 gene variations, increasing chances of early detection and treatment. The guidelines also acknowledge potential downsides of screening, including false-positive results and encourage careful patient counseling.
A new study finds that cancer patients are at a greater risk of developing diabetes, particularly those with lung, pancreatic, breast, brain, urinary tract, or uterine cancers. The study also shows that cancer patients who develop diabetes die sooner than survivors without diabetes.
A study found that high fat diets and synthetic substances in unregulated athletic performance enhancers can activate a receptor accelerating the progression of pre-cancerous lesions to pancreatic cancer in mice. Limiting exposure to these substances may help prevent pancreatic cancer development.
Adding diffusion-weighted MRI to conventional MRI enhances the differentiation of locally recurrent tumor and post-surgical fibrosis in pancreatic ductal adenocarcinoma resection. The study found higher sensitivity with DWI, facilitating earlier detection of recurrences.
A study has found that patients with pancreatic ductal adenocarcinoma (PDAC) are six times more likely to have had gallstone disease within the year prior to diagnosis than non-cancer patients. This association suggests that gallstones could be a warning sign for this aggressive and deadly cancer.
Research suggests gallstone disease may be an early indicator of pancreatic cancer, with patients having gallstones nearly six times more likely to develop the disease. This association could lead to earlier diagnosis and treatment, potentially improving survival rates for pancreatic cancer patients.
Researchers at Oregon State University have discovered a promising approach to treating pancreatic cancer, which has a low survival rate. The study found that a liposomal prodrug outperformed traditional treatments in cancer cell cultures and animal models.
UTSW researchers have identified a subset of cancer-associated fibroblasts that can be targeted to enhance immunotherapy in pancreatic cancer patients. The study found that these cells, known as antigen-presenting cancer-associated fibroblasts (apCAFs), interact with immune cells by displaying proteins called antigens on their surface.
Canada's cancer rates are declining overall, but new cases and deaths are on the rise due to an aging population and growing numbers. Despite this, efforts in cancer prevention, screening, early detection, and treatment have led to improved survival rates for those diagnosed with cancer.
A new study from University of Gothenburg found that men with high childhood BMI are at an elevated risk of obesity-related cancer, even if their weight is normal in young adulthood. The study analyzed data from 6,565 men born between 1945 and 1961 and found a persistently increased risk of adult obesity-related cancer.
Researchers at Cedars-Sinai have developed an AI tool that accurately predicts pancreatic cancer patients based on CT scan images. Lowering blood cholesterol has also been shown to slow the growth of prostate cancer by enhancing immune cell action. Additionally, a new study found that an ultrasound probe plugged into a smartphone can b...
A new study indicates that artificial intelligence can accurately predict who will develop pancreatic cancer based on pre-diagnostic CT scan images. The AI tool was trained to analyze textural differences in the pancreas and achieved an accuracy rate of 86% in identifying those who would eventually develop the disease.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
Researchers identified estrogen-related receptor gamma (ERR γ) as crucial for preventing pancreatic auto-digestion in mice. In humans, lower levels of ERR γ were found in cells affected by pancreatitis. These findings suggest new therapies regulating ERR γ activity could help prevent or treat these conditions.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
The Lustgarten Foundation has awarded a $5 million grant to Break Through Cancer to target KRAS in pancreatic cancer. The Conquering KRAS in Pancreatic Cancer Team will integrate clinical and laboratory approaches to understand why patients respond to new therapies.
The Lustgarten Foundation has awarded Career Development Grants to Pingping Hou and Edwin Manuel to fund research on pancreas cancer. Their projects focus on immune cell populations and nutrient uptake by cancer cells, aiming to develop novel therapies.
Researchers at Columbia University are studying the effects of heavy ion radiation therapy on hard-to-treat cancers, aiming to improve treatment outcomes. The new linac booster will help scientists better understand how carbon ions work against cancer, potentially leading to more effective therapies.
An AI model developed by researchers identified a subset of individuals with a 25-fold risk of developing pancreatic cancer within three to 36 months. The model used sequence of medical diagnoses from patient records to predict risk, which was validated in two independent datasets.
Dr. Philip D. Greenberg has been elected as the American Association for Cancer Research President-Elect for 2022-2023. He will work to harness advances in cancer research and translate them for patient benefit, with a focus on addressing disparities in minority engagement.
Researchers found that pancreatic cancer cells trigger the breakdown of collagen proteins, which increases arginine levels and signals stellate cells to build fibrotic meshes around tumors. This process, known as desmoplasia, creates a dense environment that promotes aggressive growth and blocks access to therapies.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Scientists at Albert Einstein College of Medicine have developed a novel therapeutic strategy that uses bacteria to deliver tetanus toxin into pancreatic tumor cells, inducing an immune response and killing the cancer. The treatment has shown promise in reducing cancer metastases by 87% and increasing mouse lifespan by 40%.
A ketogenic diet has been shown to starve pancreatic cancer cells and enhance the effectiveness of a triple-drug therapy. The study, led by TGen, found that the diet reduced glucose levels in tumors and elevated ketone bodies, leading to increased stress on cancer cells.
A novel screening platform has successfully detected over 95% of stage 1 pancreatic cancers using artificial intelligence-enabled protein marker analysis, outperforming current liquid biopsy tests in accuracy. This technology holds promise for early cancer detection and reducing mortality from this deadly disease.
A new clinical trial, named after Dr. Nate Nieto, aims to test the efficacy of a Vemurafenib and Sorafenib combination against advanced pancreatic cancer. The trial will involve about 10 patients with specific KRAS gene mutations, using liquid biopsy blood tests to identify different types of mutations.
Researchers have discovered that cancer cells carrying a common mutation accumulate large amounts of ferrous iron, which can be exploited to deliver powerful anticancer drugs. The therapeutic strategy could treat various cancers driven by KRAS mutations.
A new study found that dual-eligible patients for Medicare and Medicaid have poorer outcomes and higher costs after cancer surgery, even in high-quality hospitals. These patients are more likely to experience complications, longer hospital stays, and lower chances of going home instead of a nursing facility.
Researchers identified a molecular signature of 27 microorganisms in stool samples that can predict pancreatic ductal adenocarcinoma risk and diagnose earlier stages. The study suggests a non-invasive, rapid, and affordable diagnostic kit could be developed to detect the disease.
Research suggests that changes in the microbiome may play a role in both the development and progression of pancreatic cancer. A distinct gut microbial profile was observed in patients with ductal pancreatic cancer compared to those without the disease, and this signature consistently identified patients regardless of disease stage.
Researchers have identified a genetic signature of 27 microorganisms in stool samples that can predict the risk of pancreatic ductal adenocarcinoma and diagnose patients with earlier stages of the disease. This breakthrough could lead to an effective, non-invasive way to detect pancreatic cancer early.
Researchers have discovered a new treatment that blocks inflammation in pancreatic cancer, making it sensitive to chemotherapy and immunotherapy. The therapy more than doubled survival rates in mice with pancreatic cancer, providing promising results for future human trials.
A team of researchers from Charité – Universitätsmedizin Berlin have elucidated the process underlying drug resistance in aggressive pancreatic cancer. They found that inhibition of the RUNX1 protein limits cancer growth and may lead to effective treatment options.
Researchers discovered that cancer cells use a combination of proteins to repel T cells and protect themselves from the immune system. By disabling this protection, scientists were able to allow T cells to infiltrate and attack pancreatic tumors, leading to shrinkage or disappearance.
A new study suggests that common blood pressure medications can prolong survival for pancreatic cancer patients. The study found that patients who took ARB-type therapies and ACE inhibitors had a lower risk of mortality compared to those who did not.
A Toronto study found that certain probiotic bacteria can alter the function of immune cells and spur cancer growth in pancreatic cancer. Deletion or inhibition of a key protein enabled better treatment sensitivity and more inflammatory T cells, while activation thwarted these effects.
Researchers at the University of Illinois Chicago have developed a compound that may offer hope for pancreatic cancer treatment. The experimental compound, XP-524, has been shown to more than double the average survival time for mice with pancreatic cancer when combined with immunotherapy.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers have designed a nanoparticle system that can deliver fluorescent dyes to diagnose and treat pancreatic cancer tumors. The system overcomes the challenge of reaching cells deep within dense tumor masses, enabling detailed images of tumor structures and potentially targeted therapies.
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
A recent study has found that faulty versions of the BRCA1 and BRCA2 genes are associated with an increased risk of developing prostate and pancreatic cancers in men. The study analyzed data from over 3,200 families and estimated that men who carry a BRCA2 mutation have a 27% risk of developing prostate cancer by age 80.